Darbepoetin Alfa Dosing and Administration

Introduction to Darbepoetin Alfa

The FDA-approved starting dose of Darbepoetin Alfa is either 2.25 mcg/kg weekly or 500 mcg every 3 weeks subcutaneously, while Epoetin Alfa is dosed at 150 U/kg three times weekly or 40,000 U weekly, according to the FDA 3, 1, 4

For a patient receiving Epoetin Alfa-epbx 10,000 units subcutaneously once weekly, convert to Darbepoetin Alfa 40 mcg (40,000 units) subcutaneously once weekly, or alternatively 100 mcg (500 mcg) subcutaneously every 3 weeks, as recommended by Blood advances 1, 2
The standard fixed-dose equivalent is 40,000 units (40 mcg) of Darbepoetin Alfa weekly, which corresponds to approximately 40,000 units of Epoetin Alfa weekly, based on studies published in Blood advances 1, 2

If patient is on 10,000 units Epoetin Alfa weekly: Start Darbepoetin Alfa 40 mcg (40,000 units) subcutaneously once weekly, as recommended by Blood advances 1, 2
Alternative extended interval: Consider 500 mcg every 3 weeks for improved convenience, according to Blood and Blood advances 3, 1

After 4 weeks of therapy: If hemoglobin increases by <1 g/dL and remains below 10 g/dL, increase to 60,000 units weekly, as recommended by Blood advances 1
After 4 weeks of therapy: If hemoglobin increases >1 g/dL in 2 weeks, decrease dose by 40%, based on studies published in Blood advances 1
After 4 weeks of therapy: If hemoglobin exceeds level needed to avoid transfusion, withhold dose until hemoglobin approaches transfusion threshold, then restart at 40% below previous dose, as recommended by Blood advances 1

Hemoglobin monitoring: Weekly during first weeks until stabilization, according to Praxis Medical Insights: Practical Summaries of Clinical Guidelines 5
Iron studies: Measure serum iron, TIBC, and ferritin before initiating treatment and periodically throughout therapy, as recommended by Blood advances and Praxis Medical Insights: Practical Summaries of Clinical Guidelines 1, 5

Darbepoetin Alfa carries increased risk of thromboembolism compared to no ESA therapy, according to Blood and Journal of Clinical Oncology 3, 4, 6
Exercise particular caution in patients with prior thrombosis history, surgery, immobilization, or multiple myeloma patients receiving thalidomide/lenalidomide with doxorubicin or corticosteroids, as recommended by Blood 3, 4

Maintain hemoglobin at lowest concentration needed to avoid transfusions, according to Blood advances 1, 2
Target stable hemoglobin of approximately 12 g/dL without requiring transfusions, as recommended by Praxis Medical Insights: Practical Summaries of Clinical Guidelines 5
Do not initiate therapy if hemoglobin ≥10 g/dL, according to Blood advances 1, 2